Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S. Mei M, et al. Among authors: farol l. Biol Blood Marrow Transplant. 2019 May;25(5):e183-e185. doi: 10.1016/j.bbmt.2019.01.025. Epub 2019 Jan 29. Biol Blood Marrow Transplant. 2019. PMID: 30708188 Free article.
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Mei MG, et al. Among authors: farol lt. Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. doi: 10.1016/j.bbmt.2017.07.006. Epub 2017 Jul 18. Biol Blood Marrow Transplant. 2017. PMID: 28733266 Free PMC article.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Among authors: farol l. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T, Li S, Zhang J, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Sahebi F, Sandhu K, Spielberger R, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Mei M, Aldoss I, Koller P. Othman T, et al. Among authors: farol l. Am J Hematol. 2024 Aug;99(8):1636-1639. doi: 10.1002/ajh.27365. Epub 2024 May 27. Am J Hematol. 2024. PMID: 38800943
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Othman T, et al. Among authors: farol l. Am J Hematol. 2024 Sep;99(9):1680-1690. doi: 10.1002/ajh.27378. Epub 2024 May 28. Am J Hematol. 2024. PMID: 38804599
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Othman T, et al. Among authors: farol l. Br J Haematol. 2024 Jul;205(1):368-372. doi: 10.1111/bjh.19521. Epub 2024 May 26. Br J Haematol. 2024. PMID: 38797530 No abstract available.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Ladbury C, Sanchez J, Chowdhury A, Palmer J, Liu A, Stein A, Htut M, Farol L, Cai JL, Somlo G, Rosenzweig M, Wong JC, Sahebi F. Ladbury C, et al. Among authors: farol l. Am J Clin Oncol. 2024 Jul 1;47(7):325-332. doi: 10.1097/COC.0000000000001095. Epub 2024 Mar 14. Am J Clin Oncol. 2024. PMID: 38483213 Clinical Trial.
Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
Stein AS, Al Malki MM, Yang D, Palmer JM, Tsai NC, Aldoss I, Ali H, Aribi A, Artz A, Dandapani S, Farol L, Hui S, Liu A, Nakamura R, Pullarkat V, Radany E, Rosenthal J, Salhotra A, Sanchez JF, Spielberger R, Marcucci G, Forman SJ, Wong J. Stein AS, et al. Among authors: farol l. Transplant Cell Ther. 2022 Jul;28(7):368.e1-368.e7. doi: 10.1016/j.jtct.2022.03.025. Epub 2022 Apr 6. Transplant Cell Ther. 2022. PMID: 35398328 Free PMC article. Clinical Trial.
18 results